预混胰岛素与长效胰岛素类似物治疗初诊2型糖尿病的疗效比较  

Comparison of therapeutic effect of premixed Novolin 30R insulin versus insulin glargine added to metformin and/or acarbose in newly diagnosed type 2 diabetics

作　　者：顾云娟[1] 崔世维[1] 朱湘竹[2] 袁瑾[1] 陈炜[1] 唐祝奇[1] 袁洁[1] 张荣萍[1] 

机构地区：[1]南通大学附属医院内分泌科,江苏南通226001 [2]南通大学公共卫生学院

出　　处：《中国糖尿病杂志》2010年第3期190-192,共3页Chinese Journal of Diabetes

摘　　要：目的比较诺和灵30R与甘精胰岛素强化治疗初诊2型糖尿病(T2DM)的疗效。方法将200例初诊T2DM患者随机分为两组,分别采用诺和灵30R(A组)或甘精胰岛素(B组)进行24周的强化治疗,比较两组一般情况及血糖控制情况。结果治疗后两组的血糖、血压均达到目标水平,降低程度相似。A组较B组低血糖发生率更高,体重增加幅度更大。结论诺和灵30R与甘精胰岛素对初诊T2DM的降糖效果相似,但前者的低血糖风险大,体重增加幅度大,说明甘精胰岛素更适合于初诊T2DM患者。[ Objective To compare the effects of two different kinds of insulin Novolin 30R versus glargine in newly diagnosed type 2 diabetes. Methods A total of 200 individuals were randomly divided into two groups： insulin Novolin 30R （n= 100,group A） and insulin glargine （n= 100,group B） added to metformin and/or acarbose for 24 weeks respectively. The general conditions, glucose improvement were compared between the two groups before and after the therapy. Results A tatal of 162 patients completed the study. The improvements of glucose and blood pressure of the two groups were similar. More weight gain with more hypoglycemic events was noticed in group A than in group B. Conclusions Although the results of glycemic control were similar between two groups, insulin Novolin 30R attributed to more hypoglycemia and weight gain than insulin glarine.

关 键 词：糖尿病 2型 初诊 强化治疗 

分 类 号：R587.1[医药卫生—内分泌]